Redox-Sensitive liposomes for glioblastoma treatment.

Lund, Mette Aagaard; Bak, Martin; Kamaly, Nazila; Andresen, Thomas Lars

Publication date:
2016

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Redox-Sensitive Liposomes for Glioblastoma Treatment

Mette A. Lund, Martin Bak, Nazila Kamaly, Thomas L. Andresen
Technical University of Denmark, DTU Nanotech, Center for Nanomedicine and Theranostics, Building 423, 2800 Kgs. Lyngby, Denmark

Introduction

Treatment of glioblastoma remains a challenge due to inability of the drug to reach the intracellular target. Invasive glioblastoma is associated with high grade vascularization and break-down of the blood-brain barrier (BBB), which could aid in delivering drugs to the tumor site. However, once at the tumor site, the drug has to be internalized and transported to the specific target.

The aim of the current project is to develop a drug delivery system (DDS) that crosses the permeable BBB to specifically target invasive glioblastoma cells and thereby facilitate uptake. Furthermore the DDS will be activated in the tumor environment to escape the endosome and drug efflux mechanisms, thereby transporting the drug to the intracellular target. The DDS consists of a positively charged liposome formulation and redox-sensitive lipopeptides (RSLs) or non-cleavable lipopeptides (nCL) with a PEG-linker that shields the positive charge. For intracellular cleavage a cell-penetrating (CP) moiety (8-arginines or 8R) is furthermore included. The chemotherapeutic drug Doxorubicin (DOX) is loaded into the DDS for cytotoxicity experiments. The DDS concept and components are shown in Figure 1.

Results

Cleavage and Charge-reversal

HPLC analysis (Figure 2A) showed that the intact lipopeptide eluted after 13 minutes. Treatment with 10 equivmolar DTT to RSL resulted in 100 % of the RSLs being cleaved (one peak at 8 minutes), while treatment with 1 equivmolar DTT resulted in the fully cleaved peak and an extra peak, which was believed to be the cleaved RSL with DTT still attached.

Charge reversal was proven by zeta-potential measurements of the RSL liposomes prior to and after treatment with DTT (Figure 2B). A cleavage experiment (Figure 2C) indicated that the cleavage kinetics of RSL001, RSL002, and RSL003 was different with RSL001 and RSL003 being cleaved faster than RSL002 and RSL003 showing less tendency to create the DDS intermediate.

Conclusion and Perspectives

It has been shown that RSLs can be successfully post-inserted into liposomes, thereby changing the charge and the uptake properties of the liposomes. Furthermore, cleavage of the RSLs can restore the initial properties of the liposomes. Cleavage of the three RSLs indicated different cleavage kinetics and more investigations into these kinetics and the impact on uptake will be undertaken. In the unsaturated formulation the RSLs were not cleavable after storage and the stability of the RSLs in unsaturated and saturated formulations will therefore be investigated.

Acknowledgement

The Lundbeck Foundation

This project is part of the Research initiative on Brain Barriers and Drug Delivery (RIBBDD) funded by the Lundbeck Foundation

Contact

Mette Aagaard Lund
metlun@nanotech.dtu.dk